Company: CORT
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001628280-25-037005
Chunk: 5

Company: CORCEPT THERAPEUTICS INC
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 5
---
 2024104,028 $133 $758,244 $(641,059)$258 $430,288 $547,864 Issuance of common stock under incentive award plan700 1 7,573 — — — 7,574 Shares tendered to satisfy cost and statutory withholding requirements for net settlement of cashless option exercises and vesting of restricted stock(208)— — (6,242)— — (6,242)Repurchase of common stock in connection with Stock Repurchase Program(122)— — (3,478)— — (3,478)Excise tax related to net share repurchases— — — 16 — — 16 Stock-based compensation— — 13,881 — — — 13,881 Vesting of RSAs in connection with ESPP— — 1,314 — — — 1,314 Other comprehensive loss, net of tax— — — — (174)— (174)Net income— — — — — 35,488 35,488 Balance at June 30, 2024104,398 $134 $781,012 $(650,763)$84 $465,776 $596,243 

The accompanying notes are an integral part of these condensed consolidated financial statements.

9

CORCEPT THERAPEUTICS INCORPORATED

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

1. Basis of Presentation and Summary of Significant Accounting Policies

Description of BusinessCorcept Therapeutics Incorporated (collectively, “Corcept,” the “Company,” “we,” “us,” and “our”) is a commercial-stage biopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol. In 2012, the United States Food and Drug Administration (“FDA”) approved Korlym® (“mifepristone”) 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery and in June 202